Clopidogrel Tablet, Film Coated
Product Images NDC 68645-590

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68645-590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Legacy Pharmaceutical Packaging, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Clopidogrel Tabs Aurobindo Walmart 1)

Chemical structure of Clopidogrel Bisulfate, showing its molecular formula with various chemical bonds and functional groups, including a thiophene ring, a chlorophenyl group, and a sulfate ion (H2SO4).*

FDA Label Image

Clopidogrel Tablets, Usp 75mg (Clopidogrel Tabs Aurobindo Walmart 10)

Label for Clopidogrel Tablets USP, 75 mg, film-coated tablets in a container of 90 tablets. The label shows the product name, dosage strength, tablet images with imprints, and handling information. Distributed by Wal-Mart and manufactured for Aurobindo Pharma USA with packaging by Legacy Pharmaceutical Packaging LLC.*

FDA Label Image

Figure 1 (Clopidogrel Tabs Aurobindo Walmart 2)

A horizontal bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel Bisulfate 75 mg. The chart compares the change in active metabolite AUC relative to Clopidogrel alone for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with mean values and 90% confidence intervals shown for each PPI.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Tabs Aurobindo Walmart 3)

A line chart showing cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. It compares placebo plus aspirin versus clopidogrel bisulfate plus aspirin with event rates plotted against months of follow-up, including a p-value of 0.00009 indicating statistical analysis.*

FDA Label Image

Figure-3 (Clopidogrel Tabs Aurobindo Walmart 4)

A forest plot displaying subgroup analyses comparing hazard ratios between Clopidogrel Bisulfate and placebo across various patient demographics and clinical characteristics. It includes categories such as age groups, gender, race, diabetic status, previous medical history, and concomitant medication use, showing the relative favorability of Clopidogrel Bisulfate versus placebo with confidence intervals.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Tabs Aurobindo Walmart 5)

A line graph comparing the percentage of deaths before first discharge over days since randomization (up to 28 days) between placebo and Clopidogrel groups. The graph shows death percentages and total deaths for placebo and Clopidogrel, with a noted 7% proportional risk reduction for Clopidogrel (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Tabs Aurobindo Walmart 6)

A Kaplan-Meier curve comparing the percentage of patients with death, reinfarction, or stroke before first discharge between Clopidogrel and placebo groups over 28 days since randomization. The graph shows lower event rates for Clopidogrel (9.2%) compared to placebo (10.1%), indicating a 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Tabs Aurobindo Walmart 7)

A forest plot chart displaying odds ratios with 99% confidence intervals comparing Clopidogrel Bisulfate to placebo across various subgroups, including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart visually indicates whether each subgroup favors Clopidogrel Bisulfate or placebo.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Tabs Aurobindo Walmart 8)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. The graph compares two treatments labeled Aspiring and Clopidogrel Bisulfate, showing event rates increasing over time, with aspirin exhibiting a slightly higher cumulative event rate. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Tabs Aurobindo Walmart 9)

A forest plot chart comparing the hazard ratios of Clopidogrel Bisulfate and Aspirin across qualifying conditions including Stroke, MI, and PAD. The chart shows the number and percentage of events for each drug within these conditions, with a horizontal line indicating the hazard ratio range from 0.6 to 1.3 and markers favoring either Clopidogrel Bisulfate or Aspirin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.